According to the recent research report titled ‘Global Gout Therapeutics Market is Segmented by Drug class type (Antihyperuricemic Agents, Non-steroidal Anti-inflammatory Drugs, Corticosteroids, Colchicine, Other Drug Classes); by Application type (Acute Gout and Chronic Gout), Regional Forecasts 2021-2027’, available with MarketStudyReport, global gout therapeutics market size is expected to grow considerably over 2021-2028.
 

Growing biologics adoption, increased R&D on regeneration pharmaceuticals for therapy, and rising prevalence of gout with increased alcohol consumption are the primary drivers of global gout therapeutics market expansion, cites the study.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/4219670/
 

Notably, the Australian Bureau of Statistics and the National Health Survey 2017-2018, 0.8% of the country’s population suffered from gout conditions. Gout is more commonly found in males as compared to females, with nine out of ten patients suffering from gout being males.
 

Rising alcohol consumption, high-purine diet, mounting cases of obesity and renal disease, and surge in usage of drugs like diuretics are likely to contribute to an increase in gout cases.
 

For the unversed, gout is a kind of inflammatory arthritis that can be quite painful over time and affects one joint at a time. The symptoms intensify with time, which is known as a flare, and other times, there are no symptoms, which is known as remission. Though gout has no cure, it can be effectively treated and managed with a change in lifestyle, medicine, and self-management measures.
 

Speaking of challenges, side effects associated with the therapeutic drugs and high indirect cost of therapies are anticipated to hamper global gout therapeutics industry remuneration scope over the study period.
 

Elaborating on geographical ambit, Asia Pacific market is anticipated to showcase notable growth over the forecast period, owing to rising investment by major players, growing adoption of gout therapies, and increasing number of patients. Moreover, elevated risk of gout due to rising alcohol intake and smoking behaviors, as well as stressful lifestyles are expected to contribute to the regional industry expansion.
 

With respect to the competitive terrain, Teijin Pharma Ltd., Takeda Pharmaceutical Company Ltd., Romeg Therapeutics LLC, Regeneron Pharmaceuticals Inc., Novartis International AG, Mylan N.V., Horizon Therapeutics plc, GlaxoSmithKline plc, Boehringer Ingelheim, and Lannett Company Inc. are the key players influencing global gout therapeutics market trends.